-
Loading metrics
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
- Paweł Gunerka,
- Kamila Gala,
- Martyna Banach,
- Jakub Dominowski,
- Joanna Hucz-Kalitowska,
- Krzysztof Mulewski,
- Agnes Hajnal,
- Endre G. Mikus,
- Damian Smuga,
- Marcin Zagozda,
- Krzysztof Dubiel,
- Jerzy Pieczykolan,
-
Beata M. Zygmunt ,
Roles Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing
* E-mail: Beata.Zygmunt@celonpharma.com
Affiliation CelonPharma Innovative Drugs Research & Development Department, Celon Pharma S.A., Lomianki, Poland
⨯ - Maciej Wieczorek
http://orcid.org/0000-0002-1680-7226
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
- Paweł Gunerka,
- Kamila Gala,
- Martyna Banach,
- Jakub Dominowski,
- Joanna Hucz-Kalitowska,
- Krzysztof Mulewski,
- Agnes Hajnal,
- Endre G. Mikus,
- Damian Smuga,
- Marcin Zagozda
x
- Published: July 23, 2020
- https://doi.org/10.1371/journal.pone.0236159